MK-677 side effects: separating bloat panic from actual clinical data

What did @nickdubpharma actually say?

The creator argued that MK-677 is a worse option than exogenous HGH because of how it works mechanically. His core point: MK-677 activates the ghrelin receptor (GHS-R1A), which drags along unwanted ghrelin-related effects, including higher appetite, cortisol, prolactin, and worsened insulin sensitivity. He also claimed that exogenous HGH offers "predictable pharmacokinetics" and can be "adjusted or stopped quickly," while MK-677 depends on pituitary function that may already be compromised. He wrapped up by saying "studies and user blood work often show stronger increases in fasting glucose and insulin resistance markers" on MK-677 compared to low-to-moderate HGH use.

Worth noting: the caption calls MK-677 users "bloated diabetic losers," which is editorializing, not pharmacology. The actual transcript is more measured, though still one-sided in how it frames the comparison.

Does the science back this up?

Partially, yes. The mechanism he describes is largely accurate, but the comparative claim that MK-677 produces worse metabolic outcomes than equivalent HGH doses is not well-supported by head-to-head trial data.

MK-677 does activate GHS-R1A, and ghrelin receptor agonism does produce appetite stimulation and modest cortisol elevation. That part is solid. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) confirmed that MK-677 increases GH and IGF-1 in older adults, with notable insulin resistance as a documented side effect. Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) similarly showed increased fasting glucose in elderly subjects on MK-677.

However, exogenous HGH also reduces insulin sensitivity, and that effect is dose-dependent and well-documented. The claim that MK-677 is categorically worse for blood sugar than "equivalent" HGH doses lacks a robust comparative clinical trial. That comparison leans heavily on anecdote and user bloodwork, which is not the same thing as peer-reviewed evidence.

What did they get wrong (or right)?

He got the mechanism right. He got the side effect profile roughly right. Where he overreaches is the comparative framing.

The claim that MK-677 delivers "weaker IGF-1 elevation" when pituitary function is compromised is plausible but largely unverified in clinical literature for healthy adults. Most trials showing meaningful IGF-1 elevation from MK-677 used populations with age-related GH deficiency, not bodybuilders with varying pituitary reserve.

He is also selectively framing HGH as the cleaner option. Exogenous HGH carries its own risks: carpal tunnel syndrome, fluid retention, potential acromegalic changes with chronic use, and yes, insulin resistance. Van der Lely et al. (2001, Endocrine Reviews) documented these well. Describing HGH as simply having "clear dose response" without mentioning those risks is incomplete at best.

What he got right: prolactin elevation from ghrelin receptor activation is a real and often underreported effect of MK-677, and the appetite-stimulating mechanism is genuinely difficult to separate from the compound's GH-releasing action. That is a fair clinical point.

What should you actually know?

If you are considering MK-677, the side effect profile is real and worth understanding before starting. Insulin resistance, water retention, increased appetite, and potential cortisol elevation are documented, not just gym-forum rumors. Anyone with pre-diabetes, metabolic syndrome, or elevated fasting glucose should approach this compound with serious caution and physician oversight.

That said, MK-677 is not a scheduled substance in the U.S., while exogenous HGH is a controlled compound requiring a prescription. The practical and legal landscape for individuals considering these options is very different. Framing this purely as a pharmacological comparison, as this video does, ignores a significant real-world variable.

Neither MK-677 nor exogenous HGH has been approved by the FDA for the performance or body composition uses described in this video's implied context. The research that does exist for MK-677 is largely in elderly, GH-deficient, or cachexic populations. Extrapolating those findings to healthy adults seeking body composition changes is a stretch that neither this creator nor the literature fully supports.

If you are working with a telehealth provider on peptide therapy, ask specifically about fasting glucose monitoring, HbA1c baseline testing, and how long any GH-stimulating compound is intended to run. Duration matters as much as dose.